US industry spurs CBER (Center for Biologics Evaluation and Research) into action on device applications
This article was originally published in Clinica
Executive Summary
In response to industry complaints, the US FDA's Center for Biologics Evaluation and Research (CBER) plans to develop a "Device Action Plan" to determine how to speed up product reviews for medical devices that fall within its regulatory remit.